Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 18/20 | 0.60 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.51 |
| ▸ | PIM1 | P11309 | 1/20 | 0.51 |
| ▸ | CDK8 | P49336 | 1/20 | 0.51 |
| ▸ | GSK3B | P49841 | 1/20 | 0.51 |
| ▸ | CDK7 | P50613 | 1/20 | 0.51 |
| ▸ | CDK9 | P50750 | 1/20 | 0.51 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.51 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.51 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3946560 | 1.00 | TRPV1 (0.60) | TRPV1CHEK1PIM1CDK8GSK3B | |
| SCHEMBL3946554 | 1.00 | TRPV1 (0.60) | TRPV1CHEK1PIM1CDK8GSK3B | |
| SCHEMBL3937017 | 0.99 | TRPV1 (0.61) | TRPV1CHEK1PIM1CDK8GSK3B | |
| SCHEMBL3937023 | 0.99 | TRPV1 (0.61) | TRPV1CHEK1PIM1CDK8GSK3B | |
| SCHEMBL3943231 | 0.96 | TRPV1 (0.58) | TRPV1CHEK1PIM1CDK8GSK3B | |
| SCHEMBL3943228 | 0.96 | TRPV1 (0.58) | TRPV1CHEK1PIM1CDK8GSK3B | |
| SCHEMBL3948060 | 0.96 | TRPV1 (0.58) | TRPV1CHEK1PIM1CDK8GSK3B | |
| SCHEMBL3940497 | 0.95 | TRPV1 (0.57) | TRPV1CHEK1PIM1CDK8GSK3B | |
| SCHEMBL3940320 | 0.95 | TRPV1 (0.57) | TRPV1CHEK1PIM1CDK8GSK3B | |
| SCHEMBL3941171 | 0.95 | TRPV1 (0.57) | TRPV1CHEK1PIM1CDK8GSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090203667-A1 | PENTADIENAMIDE DERIVATIVES | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2009-08-13 | — | — | US | disclosed |
| EP-2050734-A1 | PENTADIENAMIDE DERIVATIVE | Kyowa Hakko Kirin Co., Ltd. (JP) | 2009-04-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090203667-A1 | PENTADIENAMIDE DERIVATIVES | PRMT1, REN, NGLY1 | TRPV1 2741/4885CHEK1 4811/4885PIM1 1861/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.